April 10, 2007 — AGAWAM, MA — Microtest Laboratories (www.microtestlabs.com) will highlight its expanded contract manufacturing, virology, and pharmaceutical testing capabilities at the BIO International Convention, May 6-9 at the Boston Convention & Exhibition Center.
With its completion of a $7.5 million capital improvement program, Microtest has added a new state-of-the-art pharmaceutical testing laboratory, a series of segregated virology testing laboratories, new aseptic fill/finish manufacturing facilities, and purchased a MicroSeq® Microbial Identification Systemalong with the hiring of additional professional staff.
With this addition, Microtest has bolstered its services and emerged as a leader in the contract manufacturing market.
“As a customer-focused provider of both contract laboratory testing and contract manufacturing services, we offer unique cross-over benefits for our customers,” said Steve Richter, PhD, Microtest president. “These include a complete range of pharmaceutical and virology test services that can support full in-process and product release testing as well as product stability testing, raw material qualification, and assay development/validation,” added Richter.
“Moreover, since we manufacture the pharmaceutical productas a growing provider of fill/finish operationswe have all the systems and procedures in place to fully support all the requirements of the FDA, EMEA and any drug-regulating body in the world,” Richter noted.
For more information on Microtest capabilities and services, visit Richter in the Microtest booth, number 533/A20, at the BIO International Convention, May 6-9 in the Boston Convention & Exhibition Center in Boston. Or, visit the Microtest web site at www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, MA, USA, the company’s expertise and flexible processes enhance product safety and security, accelerate time-to-market, and minimize supply chain disruption.